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ABSTRACT 
Several lines of evidence are indicative of a role for immune activation in the 
pathophysiology of schizophrenia. Nevertheless, studies using positron emission tomography 
(PET) and radioligands for the translocator protein (TSPO), a marker for glial activation, 
have yielded inconsistent results. In the present thesis the primary aim was to investigate 
immune activation in brain in early schizophrenia by examining brain TSPO availability in a 
cohort of first-episode psychosis (FEP) patients, never before exposed to antipsychotics. 
In our first study we assessed the reproducibility of the second generation radioligand 
[11C]PBR28 by performing repeat measurements in 12 healthy control subjects. We found a 
medium test-retest reproducibility, but high reliability in [11C]PBR28 binding. A numerically 
lower variability was detected for subjects examined in the morning of separate days, as 
opposed to morning and afternoon of the same day, where higher afternoon TSPO levels 
were observed using secondary methods of quantification. The results suggest that diurnal 
variation may be a potential confounder in clinical studies. 
In our second study we examined 32 healthy individuals, using [11C]PBR28, of which 26 had 
repeat PET measurements. We found a strong association between TSPO availability in brain 
and blood cells, both at baseline and when analyzing change between two PET examinations. 
There was also a significant correlation between change in peripheral leukocyte numbers and 
change in brain TSPO. The results suggest interplay between central and peripheral TSPO at 
physiological conditions, and that measurement of radioligand binding in blood cells may be 
a way to control for peripheral immune function in PET studies of TSPO in brain. 
In our third study we examined 16 antipsychotic-naïve FEP patients and 16 control subjects 
with PET and [11C]PBR28. A significant decrease in TSPO availability in brain was detected 
in patients as compared to controls. The results indicate that the lack of increase in TSPO 
availability in earlier studies of schizophrenia was not caused by antipsychotic medication. 
The observed decrease suggests reduced numbers or altered function of immune cells in brain 
in early schizophrenia.  
Finally, we examined the same cohort of FEP patients and control subjects with respect to the 
relationship between TSPO availability in brain and peripheral blood cells, as well as 
chemokine levels. The ratio between binding in brain and blood cells was significantly lower 
in patients as compared to control subjects. Moreover, we observed a correlation between 
TSPO binding in brain and levels of the chemokine YKL-40 in cerebrospinal fluid, in 
different directions among patients and controls respectively. These preliminary results 
suggest a dysregulation of brain immune cells in early schizophrenia.  
Future studies combining TSPO PET with pro- and anti-inflammatory immune markers are 
needed to clarify the role of the immune system at different stages of the disease. 
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1 INTRODUCTION 
1.1 RATIONALE FOR THIS THESIS 
Schizophrenia is a life-long, often disabling disease, affecting young people on the threshold 
of adult life. Apart from the obvious suffering due to the severity of symptoms, the 
schizophrenic patient has an increased risk of somatic morbidity, in particular cardiovascular 
disease, an increased risk of concomitant substance abuse and, moreover, an increased risk 
for suicide, which leads to a life expectancy of 10-25 years less than non-schizophrenic 
individuals (1, 2). In addition, the disease leads to increased yearly costs for society estimated 
at around half a million Swedish kronor per individual (3). Existing treatment is insufficient 
and only a minority of patients reach full remission. Thus, the discovery of novel treatment 
possibilities is crucial in order to improve patients’ lives and reduce costs. However, the 
pathophysiology of the disease is not fully understood. Involvement of the immune system 
has been suggested in the development of schizophrenia, indicated by several lines of 
research (4). Microglia cells of the central nervous system (CNS) play a crucial role in the 
immune response of the healthy brain, and activation of microglia has been suggested as a 
possible pathophysiological mechanism in schizophrenia (5, 6). 
With position emission tomography (PET) it is possible to image the chemistry in the brain in 
vivo. For the past decade, PET studies have been conducted imaging the translocator protein 
(TSPO), seen as a marker for activated microglia, however with inconclusive results. 
The general aim for this thesis was to evaluate the reproducibility of a recently developed 
PET radioligand for the TSPO receptor, [11C]PBR28, in healthy subjects, and thereafter 
investigate TSPO as a biomarker in early schizophrenia. 
1.2 SCHIZOPHRENIA 
Even though patients suffering from both depression and mania have been described quite 
frequently in history, the first clear description of schizophrenia is found in a case-report from 
London as late as 1810 (Haslam 1810). During the 19th century a series of case reports of 
psychotic illnesses were published and at the same time the idea emerged that psychiatric 
illness could be treated.  
1.2.1 Definition 
At the end of the 19th century the German psychiatrist Emil Kraepelin brought together the 
three concepts hebephrenia, catatonia and paranoia into the new diagnosis dementia praecox 
(Kraepelin 1893). Later the Swiss psychiatrist Eugen Bleuler coined the term schizophrenia 
for this condition (Bleuler 1911), and described the four characteristic symptoms of the 
illness: autism, ambivalence, disturbances of association and affective disturbances.  
According to the American Psychiatric Association’s fourth version of the Diagnostic and 
Statistical Manual of Mental Disorders the following criteria for schizophrenia must be met:  
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Characteristic symptoms: Two (or more) of either:  
1. Delusions  
2. Hallucinations   
3. Disorganized speech  
4. Grossly disorganized or catatonic behavior   
5. Negative symptoms (for example lack of motivation or poverty of speech)  
Each of these symptoms should be present for a significant portion of time during a 1-month 
period (or less if successfully treated). In addition, social and/or occupational dysfunction 
must be present, and the duration of the disturbance must be at least six months (or less if 
successfully treated). Furthermore, schizoaffective disorder, mood disorder and substance 
abuse or a general medical condition must be excluded. In May 2013 the latest version of the 
diagnostic and statistical manual, DSM-5, was launched. This version contains minor changes 
to the definition of schizophrenia, however, the abovementioned main characteristics of the 
disease remain intact (7). 
1.2.2 Cognitive deficits 
Kraepelin’s observation of dementia as part of the disease later named schizophrenia captured 
both the negative symptoms and cognitive deficits most often apparent in schizophrenia. 
Indeed, cognitive impairment has since been established to constitute part of the disability in 
schizophrenia (8). A recent meta-analysis of cognition in neuroleptic-naïve, early 
schizophrenia confirms earlier findings, and establishes the impairment irrespective of 
medication with neuroleptics (9). 
1.2.3 Epidemiology 
1.2.3.1 Prevalence and incidence 
Schizophrenia affects young people on the verge of adulthood, with a similar prevalence 
worldwide. A meta-analysis of international studies estimated the point prevalence to 0.46 % 
(10), comparable to the prevalence 2005 in Stockholm of 0.35 % (department of Public 
Health, Karolinska Institutet). However, incidences differ. A review of 100 studies from 33 
countries reveal a rather large range of incidences between the different studies (the majority 
range from 7.7 till 43.0 per 100 000) with a median of 15.2 per 100 000 individuals and year 
(11). This can be compared to the yearly incidence in Stockholms Län of 20-25/100 000 
inhabitants (department of Public Health Epidemiology, Karolinska Institutet).  
1.2.4 Risk factors 
The cause of schizophrenia is to a great extent poorly understood, but several factors have 
been associated with an increased risk for developing the disease. The largest single risk 
factor is, however, heredity. 
  11 
1.2.4.1 Heritability  
In one meta-analysis of twin studies in schizophrenia, heritability has been estimated at 81 % 
(95 % confidence interval 73-90 %) (12). However, in the general population heritability 
estimates tend to be lower, and an estimate calculated from the Swedish Multi-generation 
Register was 64 % (13). 
1.2.4.2 Pregnancy and birth 
Having an older father is associated with an almost three times increased risk for 
schizophrenia (14, 15), and complications during pregnancy and birth also contribute to an 
increased risk of later developing the disease (16). Moreover, infections, such as Influenza 
virus and Toxoplasma Gondii, during pregnancy have been associated with later onset of 
schizophrenia (17–19). 
1.2.4.3 Socioeconomic status and urbanicity  
The risk of developing schizophrenia increases for individuals growing up in an environment 
of low socioeconomic status (20). It has also been demonstrated that the incidence rate is 
higher in urban than in rural settings (11), however, a later review from the same group 
investigating the prevalence of the disease showed no difference due to environment (10).  
1.2.4.4 Migration  
Both first- and second generation migrants have an increased risk of developing 
schizophrenia (21), to a greater degree for refugee migrants as compared to non-refugee 
migrants, according to a recent Swedish epidemiologic study (22). It has also been 
demonstrated that the risk increases depending on the country of origin, suggesting that 
psychosocial factors of the assimilation process may be of importance (23). 
1.2.4.5 Gender differences 
An increased risk for males of developing the disease has been shown (11). This is congruent 
with the observation that males often present more severe symptomatology and show poorer 
long-term outcome than females, however, this increased risk ratio was not accompanied with 
an increase in prevalence between the sexes (10). 
1.2.4.6 Cannabis 
Cannabis use during adolescence has been reported associated with a subsequent two-fold 
risk increase for schizophrenia, even when adjusting for confounders, such as use of other 
drugs, certain pre-morbid personality traits predisposing for schizophrenia, and the use of 
cannabis as “self medication” of incipient psychosis (24). However, later studies have 
suggested that mechanisms of genetic-environmental interplay underlie the association 
between cannabis and psychosis (25, 26). 
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1.2.5 Treatment 
The methods for calming patients that were available up to the19th century were often 
barbaric, such as imprisonment in cages, or special “coffins for lunatics” (27), and not until 
the 1930s different types of therapies, such as insulin shock, cardiazoline injections and 
lobotomy were invented (3). Of the novel therapeutics developed at that time electro 
convulsive treatment (ECT) is the only one still in use. The breakthrough in schizophrenia 
therapy arrived with the invention of the neuroleptics in the 1950s. A few of the first 
introduced drugs are still in use, but numerous antipsychotics have since been developed. A 
common feature to all is blocking of the dopamine D2 receptor, even though more recent 
neuroleptics have a broader receptor profile (28) and targets for example serotonergic and 
histaminergic pathways as well. Besides neuroleptics, different types of non-pharmacological 
treatment, such as psychological treatment, psychoeducation and family intervention is often 
a necessary addition (29–31). Even so, with existing treatment only a minority of patients 
reach full remission of psychotic symptoms (32). Moreover, treatment of the cognitive 
impairment often seen in schizophrenia is complicated (33, 34), and both symptom severity 
and impaired cognition contribute to decreased quality of life (35).  
1.2.6 Pathophysiology 
Disease-specific symptoms of schizophrenia include delusions and hallucinations, implying 
defects in interpreting the meaning and source of an experience (36). Our understanding of 
the pathophysiology behind schizophrenia has increased over the years, since advances in 
neuroimaging and genetic studies have been made. Accordingly, several hypotheses have 
emerged.  
1.2.6.1 Neurodevelopmental model 
According to this model, early interference of normal neuronal development, such as synaptic 
pruning, apoptosis and axonal outgrowth, leads to later development of schizophrenia (37–
39). This disturbance is thought to arise either during early neurodevelopment, or adolescence 
(40).  The cause is suggested to be both genetic and environmental factors, such as obstetric 
complications and prenatal infections, resulting in brain pathologies leading to 
dysconnectivity, enlarged ventricles, and gray and white matter alterations (41). Indeed, 
longitudinal studies of individuals with attenuated psychotic symptoms, later developing into 
manifest psychosis, have made it possible to detect the earliest findings, such as reduced 
cortical gray matter volumes and enlarged ventricles (42–49). 
1.2.6.2 Excitation-inhibition imbalance model 
The psychotropic drug phencyclidine (PCP) and ketamine induce psychotic symptoms, 
including paranoia, depersonalization/derealization and perceptual abnormalities, mimicking 
those in schizophrenia (50). Both PCP and ketamine are antagonists of N-methyl-D-aspartic 
acid (NMDA) receptors, a receptor in the glutamatergic neurotransmission. A hypofunction 
of the NMDA receptor has been implicated in the pathophysiology of schizophrenia (51, 52), 
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and leads to an imbalance of the inhibitory/excitatory interplay of neurons (53). Elevated 
levels of the NMDA-receptor antagonist kynurenic acid (KYNA) have been demonstrated in 
both CSF and post-mortem brain of schizophrenia (54–57), (see section 1.3.5). Moreover, the 
inhibitory neurotransmitter GABA, also implicated in schizophrenia (58–61), was just 
recently found to be decreased in CSF of FEP patients, the decrease unrelated to medication 
status, and GABA levels were negatively correlated to symptom severity (62). In addition, 
recent genome-wide association studies (GWAS), as well as copy number variation (CNV) 
studies similarly implicate genes involved in glutamatergic neurotransmission (63).  
1.2.6.3 Dopamine hypothesis 
The dopamine hypothesis has dominated the field since the 1950’s. Its origin was empiric 
findings that amphetamine induces psychotic symptoms in healthy individuals and worsens 
symptoms in individuals with schizophrenia (64). Moreover, antipsychotic drugs were found 
to affect the dopamine system (Carlsson 1963), by targeting the dopamine D2-receptor (65). 
Modern imaging studies using Positron Emission Tomography (PET) have led to further 
insights into the dopaminergic system in schizophrenia. Hence, dopamine synthesis and 
release seems to be elevated in the striatum in schizophrenia, together with reduced dopamine 
release in prefrontal cortex (66–68). The striatal dopamine up-regulation has also been 
demonstrated in the prodromal phase of the disease (69).  
It has been hypothesized that NMDA hypofunction leads to changes in the neuronal 
interactions of the glutamate, GABA and dopaminergic systems (36). 
1.2.6.4 Immune hypothesis 
Immunological factors as part of the pathophysiology in schizophrenia have been discussed 
since 1845, when Esquirol described psychotic cases as an “epidemic”(70). In more recent 
years an immune hypothesis of schizophrenia has developed. Support for this hypothesis 
come from epidemiologic (71), genetic (39, 63) and clinical studies (72, 73), see below. 
1.3 INVOLVEMENT OF THE IMMUNE SYSTEM IN SCHIZOPHRENIA 
The human immune system consists of an innate immune response, mediated by for example 
neutrophils and macrophages and thought of as the first line of defense, and an adaptive 
response, involving immunological memory with T lymphocytes that recognizes antigens and 
causes destruction of infected cells and B lymphocytes that secrete antibodies (74). Links 
between schizophrenia and the immune system were assumed more than a century ago (75). 
Over the years an increasing amount of evidence point in the direction of the immune system 
as part of the pathophysiology behind the disease. 
1.3.1 Genetic studies 
In recent years, the possibility to implement large genetic studies has increased. A recent 
GWAS in schizophrenia, including more than 36 000 cases and 113 000 controls, detected 
108 genetic loci associated with schizophrenia, associations enriched among genes expressed 
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in tissues with important immune functions (63). The strongest genetic relationship in 
schizophrenia implicates variations in a locus coding for the major histocompability complex 
(MHC). The MHC locus contains genes coding for many antigen-presenting molecules, 
including complement component 4A (C4A), known to regulate synapse pruning in mice. 
Increased expression of C4A was indicated in schizophrenia, suggesting a cause for the 
reduced number of synapses found in the schizophrenic brain (39).  
1.3.2 Epidemiological studies 
Epidemiologic studies corroborate associations between schizophrenia and infection by 
several common viruses during the pre- or perinatal period (71). Moreover, there is 
significant support that severe prenatal infection and immune activation during pregnancy 
increases the risk for developing schizophrenia. This has been demonstrated in animal studies 
as well as in human epidemiological studies (76). Similarly, infection during childhood is 
associated with increased risk for later developing the illness (77).  
1.3.3 Pharmacological studies 
Anti-inflammatory agents have been proposed as add-on therapy in schizophrenia, and an 
increasing amount of reports have been published. Several studies using a Cox-II inhibitor as 
add-on to neuroleptics have demonstrated positive results in reducing psychotic symptoms 
(78). In addition, one meta-analysis of five placebo-controlled treatment studies reported a 
significant effect of non-steroidal anti-inflammatory drugs (NSAID) as augmentation therapy 
in reducing psychotic symptoms in schizophrenia (79); however, a more recent meta-analysis 
found aspirin to augment the effect of neuroleptics on psychotic symptoms, but not the Cox-
II inhibitor celecoxib (80). A way of sorting the contradictory results of these types of studies 
could be to investigate subgroups in schizophrenia, which would benefit from this add-on 
therapy. 
1.3.4 Immune markers  
1.3.4.1 Cytokines 
Cytokines are molecules involved in cell signaling, and contribute to immune cell migration 
towards sites of trauma, inflammation and infection. Elevations of several cytokines have 
been demonstrated in plasma and CSF of both medicated, chronic, as well as in early, 
neuroleptic-naive stages of schizophrenia (72, 73). These include interleukin (IL)-6, tumor 
necrosis factor (TNF)-α, IL-12, IL-1β, interferon (IFN)-γ. According to one meta-analysis, 
the most replicated plasma finding in acutely relapsed chronic patients was IL-6 and in first-
episode psychosis (FEP) patients TNF-α. However, there was no difference in plasma levels 
of IL-6 in stable, medicated patients as compared to controls (72). Another publication 
including studies of neuroleptic-naïve FEP patients reported elevated serum levels of the 
cytokines IL-1β, sIL-2r, IL-6 and TNF-α (73). Studies of cytokine levels in the cerebrospinal 
fluid (CSF) are fewer and lacking in power (72). Nevertheless, IL-6 have been found elevated 
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in CSF of chronic patients with schizophrenia (81–83), and levels of IL-1β elevated in 
medicated FEP patients (84) later diagnosed with schizophrenia. 
1.3.4.2 Chemokines 
Immune cell migration to infected or injured tissue is mediated by specific chemokines, 
chemoattractant proteins, secreted by immune cells. In addition to cell migration, functions 
include adhesion of leukocytes to vessel walls, and various tissue responses, such as 
proliferation, differentiation and angiogenesis (85). Moreover, chemokines have been 
hypothesized to play a role in the central nervous system (CNS), by having effects on 
neurotransmission, neuromodulation and even blood-brain barrier (BBB) permeability (86). 
Impact of chemokines on neurodegenerative diseases, such as multiple sclerosis (MS), stroke, 
Alzheimer’s (AD) and Parkinson’s (PD) diseases, have been demonstrated (86). Elevations of 
chemokine levels have also been proposed in psychiatric disorders, such as schizophrenia 
(87). Indeed, elevated levels of the chemokine, monocyte chemoattractant protein (MCP)-1 
have been associated with the disease (88), and the chemokine chitinase-3-like protein 1 
(YKL-40) has been genetically linked to schizophrenia (89–91).  
1.3.5 Kynurenic acid (KYNA) 
KYNA, released by astrocytes of the CNS, is a metabolite in the degradation of tryptophan, 
an antagonist to the NMDA-receptor, and has been found elevated in schizophrenia. In vitro 
findings suggest that KYNA may be of importance for both dopaminergic and glutamatergic 
neurotransmission (92). Moreover, elevated cortical KYNA levels in rats have been 
associated with impairment of cognitive domains, such as spatial working memory, learning 
and sensory gating (93), In addition, it has been proposed that the cytokine IL-6 induces 
increased production of KYNA in schizophrenia (83), suggesting a link between the immune 
system and symptoms of schizophrenia.  
1.3.6 Immune cells of the CNS 
1.3.6.1 Microglia 
Microglia cells are considered the resident macrophages of the brain and constitute 5-20 % of 
brain glial cells and around 10 % of the total cell population of the brain. At physiological 
conditions, microglia, unlike monocytes that constantly are being renewed from bone 
marrow, are maintained via self-renewal in the brain (94). In the healthy brain microglia 
appear in a ramified form, with small cellular bodies and long, slim processes. Microglia in 
this form are highly mobile, surveying the surroundings of the brain. In the damaged brain, 
either from injury, infection or neuronal dysfunction, microglia become activated, thus 
changing into a reactive, amoeboid form. In this form microglia can proliferate, phagocytose 
cellular debris and, moreover, secrete immune markers, such as cytokines, chemokines and 
neurotrophic factors, as well as present antigens (95, 96), (figure 1). 
Activated microglia can be classified in two groups, depending on the mode of activation. 
The pro-inflammatory phenotype M1 produces for example TNF-α, IL-1β and IL-6, in 
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defense against pathogens and tumor cells, however, in addition causing cell damage and 
increased inflammatory response. The anti-inflammatory M2-type microglia secretes 
cytokines, such as IL-10 and arginase-1, down-regulating inflammation and promoting repair 
and tissue remodeling (97, 98). 
1.3.6.2 Astrocytes 
Astrocytes have been reported to constitute around 20 % of the human glia cell population 
(99). Morphologically, there are four classes of astrocytes in the human brain: interlaminar, 
protoplasmic, fibrous and varicose projection astrocytes. The functions of astroglia is not 
fully understood, however, participation in intra-neuronal communication and coordination, 
metabolic support and even a role in cognitive function specific to humans have been 
proposed (100). Recent findings reveal two forms of astrocytes, the neurotoxic A1 and 
neuroprotective A2. It is proposed that activated microglia induce the A1 form by secreting 
the cytokines interleukin (IL)-1α, tumor necrosis factor (TNF) and subcomponent (C1) q after 
CNS injury, contributing to neuronal cell death. The A2-form on the other hand is induced by 
ischemia and promotes neuronal survival and tissue repair (101).  
Increases in microglia and, in some studies, of astrocytes, have previously been reported post-
mortem in the brain of schizophrenia patients (5, 6, 102, 103). However, later meta-analyses 
of post-mortem microglia and astrocyte markers are inconclusive (104, 105). The varying 
results might be due to methodological variations, such as differences in identifying and 
counting the cells and use of different immunohistochemical markers. Moreover, the most 
commonly used marker for microglia does not differentiate between the different phenotypes. 
1.3.7 Immunological interplay between the CNS and the periphery 
Previously the central nervous system (CNS) was seen as an immunologically privileged part 
of the body, due to the blood brain barrier (BBB), preventing immune cell entry from the 
periphery. However, findings during the last decade have demonstrated that there is indeed an 
interaction between peripheral immune cells and the CNS, with entrance to the CNS via the 
meninges during inflammation (106). In addition, a lymphatic system was recently 
discovered in the dural sinuses, able to carry both fluid and immune cells from the CSF, and 
connected to the deep cervical lymph nodes (107). 
1.4 POSITRON EMISSION TOMOGRAPHY 
The soft tissue of the brain is encompassed by the bony structure of the scull, preventing 
damage, but also complicating investigation of the brain. Using ionizing radiation is one 
possible measure to overcome this obstacle and study the brain in vivo. Positron emission 
tomography (PET) is an imaging technique using radiolabeled compounds, or radioligands, in 
nanomolar concentration to target specific receptors of the brain. The PET compound used 
determines what can be measured in each PET examination. The ligands are often labeled 
with a short-lived radionuclide, for example 11C, which has a half-life (T1/2) of 20.3 minutes. 
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Ideal radioligands should have a high affinity together with a high selectivity for the target, 
and if useful as a CNS-ligand must be lipophilic in order to pass the BBB (98).  
The radioligand is injected in the subject intravenously and spreads throughout the blood 
volume. Reaching the vessels of the brain, passage over the blood brain barrier (BBB) is 
necessary to enter the brain, and a small portion of the injected radioligand thus reaches the 
brain. In the brain tissue the radioligand binds to the target receptor. The radionuclide decays, 
whereby a positron is emitted. This positron travels a short distance (about 1 mm for 11C), 
until it reaches an electron, its antiparticle. This results in the annihilation of the positron-
electron pair, with the emission of a pair of photons (γ-particles) in opposite directions at 
approximately 180˚ as a consequence (108). These photons are eventually detected by the 
PET system. Two photons detected within a short time frame at an 180˚ angle are registered 
as a coincidence, and a large number of such coincidences are registered during a PET 
examination (figure 1). All coincidences at a given time point constitutes a 2D image of the 
annihilations. Placing all the 2D images from different time points of the examination in 
order creates a 3D representation of the distribution of the radioligand. 
 
Figure 1. Schematic figure illustrating collision of a positron (p+), emitted at decay of the 
radionuclide, and an electron (e-), within the brain tissue of the subject. At the site of 
annihilation (red star) the two coincidence photons (γ-particles) generated, move away at 
180o angle, and are subsequently detected by the PET system. 
Spatial resolution of an imaging system is described as the ability to discriminate between 
two closely located, separate objects that are being imaged. The spatial resolution of the high 
resolution research tomography (HRRT) system used in this thesis is approximately 1.5 mm 
in the centre, and 2.4 mm at 10 cm distance from it. 
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1.5 PET RADIOLIGANDS FOR THE IMMUNE SYSTEM 
Several possible neuroinflammatory targets have been proposed, imaging different aspects of 
the immune system of the brain. Of these the receptor of the translocator protein (TSPO) is 
the most studied (98). 
1.5.1 Imaging the TSPO receptor 
The TSPO receptor is an 18-kDa protein located in the outer mitochondrial membrane of 
many cell types of the body, including microglia and astrocytes of the CNS. Previously an 
important role in cholesterol synthesis was prevailing; however, recent findings have 
challenged this concept. Nevertheless, a role in neurosteroid synthesis and cellular energy 
consumption have been suggested (109). Expression of TSPO in the healthy human brain 
increases in response to neuroinflammation. In microglia the up-regulation of TSPO is 
relatively fast after injury, in contrast, astrocytes show a more delayed, but persistent increase 
in TSPO expression (110, 111).  
In blood, expression of TSPO have been demonstrated in monocytes and polymorphonuclear 
neutrophils in particular, and to a lesser extent in lymphocytes, platelets and erythrocytes 
(112). 
1.5.1.1 [11C]PK11195 
[11C]PK11195 is the most used of the radioligands imaging translocator protein, and up until 
some years ago the only PET tracer available for imaging TSPO. However, [11C]PK11195 
has some limitations, including poor signal-to-background noise ratio (SBR) and a high level 
of non-specific binding (113). 
1.5.1.2 Second generation TSPO radioligands 
In recent years, a large number of second-generation PET radiotracers for TSPO have been 
developed. They all share the feature of improved SBR; however, an additional trait is a 
difference in binding affinity to TSPO among human subjects. It is now established that 
approximately 10 % of the population exhibits low binding capacity to TSPO. This is 
explained by a polymorphism in the gene coding for TSPO (114), resulting in high affinity 
binders (HABs), with a single high affinity binding site for TSPO (major allele), low affinity 
binders (LABs), with a single low affinity binding site (minor allele), and mixed affinity 
binders (MABs), with equal numbers of the high and low affinity binding sites. The 
distribution of HABs, MABs and LABs in the population is approximately 49 %, 42 % and 9 
% respectively (115). However, the frequency of the minor allele differs, thus, among 
Caucasians the minor allele is present in around 30 % of the population, the major in 70 %, 
whereas the minor allele is less prevalent in African Americans (25%), Han Chinese (2%) 
and Japanese (4%) populations (114).  
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These differences in binding capacity to TSPO, using second generation radiotracers, mean 
that the binding genotype must be considered in human PET studies, in order to interpret data 
correctly. 
1.5.1.3  [11C]PBR28 
One of the second generation TSPO radioligands developed is [11C]PBR28. It has an 
aryloxyanilide structure (figure 2) and belongs to a group of proteins that exhibits high 
specific binding to TSPO. [11C]PBR28 has a 10-fold higher affinity to TSPO than 
[11C]PK11195 (116, 117). 
 
 
Figure 2. Schematic illustration of [11C]PBR28. 
 
1.5.2 Quantification of TSPO 
TSPO is present throughout the brain. Thus, when quantifying TSPO binding, no region of 
the brain is devoid of binding, and may be used as a reference region. Instead, the use of a 
compartmental model is required, using radioactivity in tissue together with radioactivity in 
arterial plasma, correcting for the metabolism of the tracer (116, 118). 
1.5.2.1 The two-tissue compartment model (2TCM) 
The two tissue compartments are defined as the radioactivity concentration of non-
displaceable radioligand in the brain (CND) and the radioactivity concentration of radioligand 
specifically bound to receptors (CS). In this model, four rate constants (K1, k2, k3 and k4) 
are used to interpret the time curves for the radioligand in different regions of the brain. This 
model has been shown to be suitable for the quantification of [11C]PBR28 binding (117), 
(figure 3, page 18). 
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Figure 3. 2TCM model: One compartment for binding in plasma (CP), and two exchangeable 
tissue compartments; one for the non-displaceable component (CND) and one for the specific 
binding (CS). K1 and k2 are rate constants for transport from plasma to tissue and back, k3 
and k4 are rate constants for transport from the non-displaceable compartment to the 
specific and back.  
1.5.2.2 Logan graphical analysis 
The linear graphical analysis, or Logan plot (119) can be used to estimate TSPO binding also 
where very low specific binding is expected. The Logan plot does not assume any particular 
model structure. The slope of the plot when the linear phase has been reached corresponds to 
the plasma volume, plus the total volume of distribution (VT) of the radioligand. The slope 
can then be expressed as follows: 
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Where K1 to k4 are rate constants, and Vp is the regional plasma volume. 
1.5.2.3 Parametric imaging 
Parametric mapping approaches can be used to filter out noise from the signal we aim to 
detect. With these algorithms outcome measures for each voxel are calculated. One example 
of parametric mapping is the wavelet-aided parametric imaging (WAPI) method. Here, signal 
patterns are identified, with the use of a “wavelet filter”, thus differentiating signal 
components (with lower frequency) to noise (higher frequency), and facilitating subsequent 
deletion of the noise (120). 
1.6 PET STUDIES OF TSPO IN SCHIZOPHRENIA 
Compared to other neurodegenerative diseases there are few PET studies of the immune 
system in schizophrenia. The two first were published less than a decade ago and used the 
older radioligand [11C]PK11195, which had previously shown elevated binding to TSPO in 
for example Alzheimer’s, Parkinson’s and Huntington’s diseases (121). These two first 
studies demonstrated an increase in TSPO binding in schizophrenic patients as compared to 
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controls (122, 123). However, the studies were small, all patients were on antipsychotic 
medication, which might influence the result (124), and moreover, the outcome measure used 
has shown low accuracy and reliability (125). Further studies of TSPO in schizophrenia have 
consequently used second generation TSPO radioligands. Takano et al used [11C]DAA1106 
and examined chronic patients, with mean duration of illness (DOI) of 18.8 (SD 2.2) years. 
No difference in binding between patients and controls was detected (126), however, authors 
did not control for TSPO genotype. In another study, using the radioligand  [18F]-FEPPA, 
patients had on-going psychotic symptoms, and shorter DOI (177.3 (SD 105.7) months), 
however, no evidence of a difference in TSPO binding as compared to controls was 
demonstrated (127). Patients in both of these studies were on medication with neuroleptics.  
One study from 2015, using [11C]PBR28, presented an increased binding both in long-term 
medicated patients and in un-medicated Ultra High Risk Individuals (128). These results 
were derived from the relative measure distribution volume ratio (DVR), as opposed to the 
volume of distribution (VT). However, this method has been criticized (129); thus, the whole 
brain (WB) values used in the normalization were ~20 % lower among patients than controls, 
seemingly driven by significant decreases in white matter of patients. In addition, WB was 
used as covariate in the statistical analysis, and not as denominator in a ratio. When the 
authors estimated TSPO binding using the 2TCM no significant difference was detected in 
either group of patients, as compared to controls.  
Since this study was presented an array of similar PET studies in schizophrenia have been 
published, using [11C]PK11195 and second generation TSPO ligands. The first used 
[11C]DPA-713 in medicated, recent-onset schizophrenia, with a DOI of 2.2 (SD 1.4) years. 
Numerical decreases in TSPO binding was seen in patients as compared to controls, however, 
no significant differences (130). In a subsequent publication, investigating [11C]PK11195 
binding in recent-onset schizophrenia (DOI 1.3 (SD 1.1) years), no difference was detected 
between patients and controls (131).  
Two additional studies have been published; one using [11C]PK11195, with a total of 16 
patients with schizophrenia (DOI 9 (SD 7) years), whereof a subgroup were neuroleptic-naïve 
(n=6) (132), and one using [18F]FEPPA, with 19 FEP patients (DOI 33.6 months), where 14 
were neuroleptic-naïve (133). None of these studies presented a difference in TSPO binding 
between patients and controls.  
Of all the TSPO studies in schizophrenia to date, only minor subgroups of patients have been 
naïve to neuroleptics, thus the impact of neuroleptics on TSPO availability have not yet been 
possible to rule out. 
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2 AIMS 
The overall objective of the thesis was to investigate the immune system in first-episode 
psychosis. The specific aims were to investigate: 
1. The reproducibility of the TSPO ligand [11C]PBR28 in healthy control subjects. 
2. The association between TSPO binding in brain and blood cells. 
3. TSPO availability in brain of neuroleptic-naïve first-episode psychosis patients.  
4. The relationship between TSPO binding in brain and peripheral blood cells, together 
with levels of chemokines, in first-episode psychosis patients. 
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3 MATERIALS AND METHODS 
3.1 ETHICAL CONSIDERATIONS 
The local Ethical review board and the Radiation Safety Committee approved all studies. The 
test-retest study in paper I was moreover approved by the Medicinal Products Agency in 
Sweden. The subjects provided verbal and written informed consent before participation.  
The PET measurement procedure is standardized and has been applied in more than 2000 
examinations in human subjects over the last 25 years. The procedure is generally well 
tolerated. During a PET measurement, each subject is exposed to radioactive energy 
equivalent to the background radioactivity which a person living in Stockholm for one year 
encounters derived from the atmosphere and surrounding buildings. 
In conjunction with the PET examination some subjects may experience discomfort by lying 
still with the head fixated during 90 minutes, and the administering of both venous and 
arterial catheters may also be perceived as uncomfortable. Lumbar punction may in rare cases 
give rise to post-puncture headache. Necessary measures to minimize the risk for adverse 
events were taken, such as the use of an experienced anesthesiologist for administering the 
arterial catheter, test of blood flow and continuous monitoring for as long as the catheter was 
in place and the use of insertion techniques that minimizes the risk for post-puncture 
headache. 
The first episode psychotic patients in papers III and IV were included directly after 
admittance for their first acute psychotic episode. At our centre, experience regarding this 
vulnerable patient group has been acquired by examining more than 100 young, neuroleptic-
naïve first-episode patients with schizophrenia in previous PET-projects. The time to plan, 
prepare and conduct the MR and PET-examinations has been performed within a week and 
does not represent a delay of initiation of antipsychotic drug treatment with regard to current 
clinical guidelines.   
When performing research, a potential risk of adverse events must be weighed against the 
benefit of advancement in knowledge about a severely disabling disease. 
3.2 SUBJECTS 
In paper I and II healthy individuals were included, whilst in paper III and IV both first-
episode psychotic patients and healthy control subjects participated.  
3.2.1 Karolinska Schizophrenia Project (KaSP) 
The clinical platform for the recruitment of patients in paper III-IV consisted of the 
Karolinska Schizophrenia Project (KaSP), a broad collaboration within the Centre for 
Psychiatric Research in Stockholm, with the overall purpose to study the immune system in 
schizophrenia. The clinical partners at the time of the studies were Norra Stockholms 
Psykiatri, Prima Barn- och Vuxenpsykiatri and Psykiatri Nordväst. 
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3.2.2 Patients 
3.2.2.1 First-episode psychosis (FEP) 
The definition of a first-episode psychosis patient differs in the literature (134). We chose to 
define an FEP patient as an individual having their first contact with a psychiatric clinic, due 
to onset of psychotic symptoms, and meeting the criteria for a schizophrenia spectrum 
disorder, according to the DSM-IV.  
3.2.2.2 Paper III-IV 
In papers III-IV 16 FEP patients, mean age 28.5 (SD 8.4) years, were recruited from 
outpatient clinics and hospital wards of three psychiatric clinics in the northwestern area of 
Stockholm (see section 3.2.1). All patients were experiencing their first episode of psychotic 
symptoms. Their mean duration of illness was 7.9 (9.6) months and total PANSS score 77.4 
(18.3). The patients had not yet been exposed to antipsychotic medication. To enable 
participation, medication with anxiolytics and sedatives was permitted, thus five patients 
received benzodiazepines (diazepam (5 mg per day) n=1 and oxazepam (10–30 mg per day) 
n=4) on the day of the PET measurement. One patient was prescribed paroxetin 20 mg per 
day. Two of the patients were nicotine smokers. A further exclusion criterium was current use 
or history of abuse of illegal drugs, including cannabis. All patients included participated in 
one PET measurement each. 
3.2.3 Healthy subjects 
Control subjects were recruited by advertisement. They were deemed healthy according to 
their medical history, physical examination, routine laboratory test and magnetic resonance 
imaging (MRI) of the brain. Moreover, a negative illegal drug-screening test, including 
cannabis, was ascertained. None of the control subjects were nicotine users. A further 
exclusion criterium was relatives with a psychotic illness. None of the healthy subjects were 
on any medication at the time of the study. 
3.2.3.1 Paper I 
Twelve healthy subjects, six males and six females, mean age 23.9 (SD 3.1) years, were 
included in paper I. In addition to the abovementioned examinations for healthy subjects, a 
Mini International Neuropsychiatric Interview (MINI) for psychiatric diagnoses was 
performed to ascertain their previous or current psychiatric health. All subjects in this paper 
performed two PET measurements each. Six subjects had the two examinations in the 
morning and afternoon of the same day, six on two separate days, 2-5 days apart. 
3.2.3.2 Paper II 
In paper II two cohorts of healthy subjects were included. Cohort one consisted of 13 
subjects, seven male and six female, mean age 24.1 (SD 3.0) years, cohort two of nine males 
and 10 females, mean age 42.2 (SD 13.4). Subjects in cohort one performed two PET 
measurements, either on the same day (n=6), or on separate days (n=7). In cohort two 13 
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subjects performed two PET measurements on separate days, and six subjects participated in 
one measurement each.  
3.2.3.3 Paper III and IV 
In paper III and IV 16 healthy control subjects were included to enable comparison with the 
FEP patients, mean age of the control subjects were 26.4 years (SD 8.4). In addition to the 
examinations mentioned in section 3.2.3, a Mini International Neuropsychiatric Interview 
(MINI) for psychiatric diagnoses was performed to ascertain their previous or current 
psychiatric health. 
3.3 MAGNETIC RESONANCE IMAGING (MRI) 
An MRI was performed in a 3 Tesla system for each subject prior to the PET examination. A 
T2-weighted sequence was used to rule out pathology and T1-weighted images for definition 
of anatomical brain regions and for coregistration with PET images. 
3.4 PET EXAMINATIONS 
The PET measurements were performed at the Karolinska university hospital in Solna, and 
the High Resolution Research Tomograph (HRRT, Siemens Molecular Imaging, USA) were 
used for all examinations. 
To fixate the head in the PET system, an individual plaster helmet was made for each subject, 
prior to the examination. Each subject achieved both a peripheral venous cannula for 
injection of the radioligand, and an arterial catheter in order to sample arterial blood 
throughout the PET examination.  
A sterile phosphate buffer (pH 7.4) containing radioligand was injected intravenously as a 
bolus over approximately 10 seconds; hereafter the cannula was flushed with a 10 mL saline 
solution. 
Brain radioactivity was measured for up to 91 minutes, except for one subject in paper I 
where the acquisition time was 60 minutes, two subjects in paper II (one in cohort 1, PET 2 
60 min.; and one in cohort 2, PET 1 50 min) and in papers III-IV one patient (85 min) and 
two controls (77 min), due to technical issues. 
3.5 ARTERIAL BLOOD SAMPLING 
An automated arterial blood sampling system (ABSS) was used during the first five minutes 
of all PET examinations. In addition, arterial blood samples were drawn manually at 
subsequent time points throughout the examinations. 
3.6 IMAGE PREPROCESSING 
In all papers, MR images were realigned, segmented and co-registered to PET images using 
SPM5 in Matlab R2007b (Wellcome Trust Centre for Neuroimaging, London, UK; The 
Mathworks, Natick, MA, USA). Correction for head movement in PET examinations was 
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performed using a frame-by-frame realignment algorithm, where all frames were realigned to 
the first minute of acquisition. 3D PET summation images were obtained by integrating 4D 
PET images over time, and reoriented MR images were thereafter co-registered to the 3D 
PET summation images, thereby creating parameters of rotation and translation. 
3.7 BRAIN REGIONS OF INTEREST 
In papers I-II regions of interest (ROIs) were defined using the Automated Anatomical 
Labelling (AAL) System in SPM5. The primary ROI in paper I was gray matter (GM), in 
addition, regional binding in thalamus, putamen, hippocampus, lateral frontal cortex and 
lateral temporal cortex (all of these brain regions considered of interest in research on the role 
of immune activation in neuropsychiatric disorders) was investigated. In paper II all AAL 
ROI’s were combined into one large whole brain (WB) ROI, since there was no hypothesis of 
a regional difference in the relationship between brain and blood cells binding. 
In papers III-IV ROI’s were defined using the FreeSurfer software (version 5.0.0) (135). The 
primary ROI of paper III was GM, in addition, white matter, frontal cortex, temporal cortex 
and hippocampus (considering their interest in research in schizophrenia, as well as for 
comparison to previous TSPO PET studies) were examined. In paper IV GM was selected as 
the primary ROI. 
3.8 METABOLITE CORRECTED ARTERIAL PLASMA INPUT FUNCTION  
Preprocessing of arterial blood was performed for all papers using Kaleidagraph 4.1 software 
(Synergy Software). In short, after dispersion correction, interpolation of manual arterial 
blood samples and integration with the continuous sampling from the ABSS was performed, 
thus creating a continuous blood time-activity curve. A plasma curve was estimated by 
multiplying the first 5 min of the blood curve by the plasma-to-blood ratio curve, and the 
remaining part of the plasma curve estimated by interpolating the discrete plasma 
measurements.  
In papers I and II, correction for radioligand metabolism, using individual parent fraction 
data, was performed in PMOD v3.2 (PMOD Technologies Ltd, Zurich, Switzerland), with a 
three-exponential model, yielding an arterial plasma input function. In papers III and IV 
correction for radioligand metabolism was performed in Matlab R2007b, using individual 
parent fraction data, thus interpolating the discrete metabolite data and multiplying it with the 
plasma, resulting in the final input function. 
3.9 QUANTIFICATION OF RADIOLIGAND BINDING 
3.9.1 2TCM 
For the main analyses in paper I and III [11C]PBR28 binding was quantified using two-tissue 
compartmental modeling, with the metabolite-corrected arterial plasma as input function (see 
also section 1.5.2.1). 
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3.9.2 2TCM-1K 
In paper III a modified 2TCM model was used in addition, in order to enable comparison 
with a previous TSPO PET study (128). In this model an additional vascular compartment is 
added. This compartment is hypothesized to account for vascular endothelial binding, and the 
uptake is thought to be irreversible. 
3.9.3 DVR 
In paper III a relative measure to estimate TSPO binding was used as well. The distribution 
volume ratio (DVR) is calculated as the ratio between regional VT and VT of a chosen 
reference region (equation 2). In this case gray matter (GM) was chosen as the region of 
interest (ROI) and whole brain (WB) as the reference region. VT of both GM and WB was 
estimated from both the 2TCM and 2TCM-1K models. Also this approach was used for 
comparison with a previous publication (128). 
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3.9.4 Logan graphical analysis 
In paper II linear graphical analysis, or Logan plot (119) was chosen to estimate [11C]PBR28 
binding, in order to quantify TSPO binding also in the LAB individual, where very low 
specific binding is expected (see also section 1.5.2.2). 
3.9.5 Parametric imaging 
In order to compare the reference ROI-based method of analysis with parametric imaging, the 
wavelet-aided parametric imaging method (WAPI) was applied in paper I (see also section 
1.5.2.3). 
3.9.6 Radioactivity in blood cells 
The blood constitutes of blood cells and plasma, according to figure 4. 
 
Figure 4. Schematic illustration of plasma and blood cells in whole blood. Figure courtesy 
Naoki Kanegawa.  
In paper II and IV the radioactivity in blood cells was calculated from the radioactivity in 
blood (CBlood) and in plasma (CPlasma) and hematocrit value (HCT), according to equation 3: 
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Generating a time activity curve (TAC) for radioactivity in blood cells. VT of blood cells was 
then estimated as the ratio of area under the curve (AUC) for blood cells, to AUC of the 
whole scan time (AUC input). 
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3.9.7 Binding in brain normalized for peripheral binding 
In paper II and IV normalized VT was calculated as follows: 
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3.10 CLINICAL EVALUATIONS  
Patients in paper III were assessed for psychotic symptoms with the Positive And Negative 
Syndrome Scale (PANSS) (136), and their level of functioning with the Clinical Global 
Impression (CGI) scale (137, 138). 
3.11 COGNITIVE TESTING 
Cognitive functioning, using the Measurement and Treatment Research to Improve Cognition 
in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) (139, 140), was 
assessed in all subjects in paper III.  
3.12 CHEMOKINES IN BLOOD AND CSF IN PAPER IV 
3.12.1 Lumbar puncture 
In paper IV lumbar puncture (LP) and blood sampling was performed in both patients and 
control subject within two weeks of PET measurements, and cerebrospinal fluid (CSF) and 
plasma was obtained for analyses of chemokine levels in 11 patients and 13 controls. 
3.12.2 Analysis of chemokines 
Levels of the chemokines YKL-40 and MCP-1 in CSF and plasma were measured using an 
electrochemiluminescence assay. In short, the Meso Scale Discovery (Meso Scale, 
Gaithersburg, MD, USA) human chemokine panel 1 kit, measuring MCP-1 (cat no. 
N05047A-1) and the human YKL-40 kit (cat no. N451MCA-1) was used, following the 
protocol set by the manufacturer (www.mesoscale.com), all samples assayed in duplicates, 
the intra-assay coefficient of variation less than 25 %.  
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3.12.3 TSPO genotyping 
All subjects were genotyped for the rs6971 polymorphism in the TSPO gene using a TaqMan 
based polymerase chain reaction assay (Applied Biosystems® QuantStudio™ 7). 
3.13 STATISTICS 
All statistical analyses were performed using IBM SPSS Statistics 22 or 23 (Armonk, NY), or 
R (version 3.2.4 'Very Secure Dishes').  
3.13.1 Paper I 
In paper I the absolute variability (V) was expressed as the difference in VT between the first 
and second PET measurements (PET1 and PET2), relative to the mean of the two values as 
follows: 
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Absolute variability (V) was calculated for each subject separately, and from these separate 
values of V, the mean absolute variability of the whole sample was calculated. 
The intraclass correlation coefficient (ICC) was calculated as follows, from McGraw and 
Wong:  
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Where k and n represent the number of observations and subjects respectively, MSSsubj, 
MSSmeth and MSSerror denote the mean sum of squares for the subjects, methods, and residual 
error respectively.  
The direction of change between two measurements was assessed using the following 
equation: 
D = (VT.PET2  VT.PET1)VT.PET1
*100    (8) 
Effect of gender and genotype on the reproducibility of [11C]PBR28 was assessed using a 
Mann-Whitney U test. Differences in radiochemical data between subjects were tested using 
the paired t test. Related samples Wilcoxon signed ranks test was used to test differences in 
[11C]PBR28 binding in the subgroup performing PET in the morning and afternoon of the 
same day, as well as group differences in radiochemical data between the two subgroups.  
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3.13.2 Paper II 
Coefficient of variance was calculated as the ratio of the standard deviation to the mean. The 
change in brain and blood cell binding was estimated according to equation 9. 
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The change in blood cell parameters, as well as the ratio between VT in brain and blood cells 
(normalized VT) was calculated in a similar fashion. Student’s t-test was used to calculate 
differences of mean VT values between HABs and MABs. Partial correlation was performed 
to investigate the relationship between VT values in brain and blood cells, with TSPO 
genotype as covariate; then separate analyses were performed using Pearson’s correlations for 
each genotype group. Partial correlations were also used to investigate the relationships 
between VT values and blood cell counts. On account of the small sample sizes, Spearman’s 
correlation was used to assess the relationship between the changes in VT values in relation to 
leukocyte cell counts, in each genotype subgroup. Pearson’s correlations were performed for 
all subjects combined in the main analyses of the relationship between change in VT between 
brain and blood cells, as well as a partial correlation, to avoid a confounding effect of 
genotype. Spearman’s correlation was performed for the separate analysis in the groups 
examined during the same day, or on separate days with short interval, respectively. 
3.13.3 Paper III 
The difference between patients and controls in [11C]PBR28 binding in GM was examined 
using a univariate analysis of covariance (ANCOVA). GM VT derived from 2TCM was used 
as dependent variable, group (patients versus control subjects) as independent variable and 
gender and genotype as covariates. Additional univariate ANCOVAs was performed to 
examine group differences in binding in frontal cortex, temporal cortex, hippocampus and 
white matter, each having sex and genotype as covariates.  
3.13.4 Paper IV 
Logistic regression was performed to investigate differences in chemokine levels between 
patients and controls, with age as covariate, due to the small sample size. An ANCOVA; with 
gender and genotype as covariates, was used to compare VT blood cells between the groups. 
Partial correlation was performed to examine the relationship between TSPO in brain and 
blood cells, with gender and genotype as covariates. Partial correlations were also performed 
to investigate the relationship between TSPO in brain and chemokine levels in CSF, and VT 
in blood cells and chemokine levels in plasma, respectively, using age, gender and genotype 
as covariates. 
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4 RESULTS AND COMMENTS 
4.1 PAPER I 
[11C]PBR28 is a second generation radioligand for the translocator protein (TSPO). The 
primary aim of paper I was to investigate the test-retest reproducibility of the ligand, by 
determining the regional volume of distribution (VT) in two consecutive PET measurements 
in healthy subjects. 12 subjects were examined twice, six in the morning and afternoon of the 
same day, and six in the morning of two different days. VT in gray matter (GM) estimated 
using a two-tissue compartmental model (2TCM) was the primary endpoint in the analysis of 
reproducibility.  
 
Figure 5. Representative figure with radioactivity data (dots) from subject 2 showing the 
2TCM-model fit (line) to the time-activity-curve (TAC) for gray matter (light blue), thalamus 
(purple), lateral frontal cortex (yellow) and hippocampus (red). 
 
The absolute variability in VT in the GM was 18.3±12.7 %. Regional ICC values ranged from 
0.90 to 0.94, except in the white matter (WM) region (0.32), where there was also a higher 
inter-individual variability (48.3±39.8 %). Calculations made separately for each genetic 
group of HABs and MABs, rendered values of VT ICC in the GM of 0.89 and 0.91, 
respectively. When reducing the time of analysis to 63 min, similar values for the variability 
in VT (16.9± 14.9 %) were obtained. 
When analyzing the subjects who performed PET on the same as opposed to separate days, 
respectively, we found a numerically lower absolute variation in the separate-day group as 
compared to the same-day group (15.9±12.2 vs. 20.7±20.7), however, not significant 
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(p=0.59) (figure 6). In the same-day group, the difference in GM VT between morning and 
afternoon examinations was significant for the 63-min (p=0.028), but not for the 91-min 
analysis. 
 
Figure 6 showing VT values for repeat measurements of the two subgroups performing PET 
in the morning and afternoon on the same day, and those with PET in the morning of 
separate days. Straight lines represent HABs, dashed MABs. VT  values in gray matter (GM) 
estimated using 2TCM. 
 
Average GM VT for the HAB subjects was 4.3±1.8 for both measurements combined. The 
corresponding value in MAB subjects was 2.6±1.1. Genotype did not affect absolute 
variability (17.6 % in MAB subjects vs. 19.1 % in HAB subjects; p=1.00). 
Using quantification with WAPI, VT in the GM of all subjects ranged between 1.3 and 7.7, 
and correlation with the 2TCM-derived values was high (r=0.989, p<0.001, all GM values 
combined, n=24). The mean difference in absolute variability between 2TCM and WAPI was 
0.6±9.0% (p=0.838). The difference between morning and afternoon examinations using 
WAPI-generated GM VT was statistically significant for both 91-min and 63-min analyses 
(p= 0.028). When using WAPI, the absolute variability in VT of the GM was 17.8±12.7% 
(figure 7, page 33). 
  33 
 
Figure 7.Woxel-wise absolute variability in all subjects, based on wavelet-aided parametric 
images (WAPI). Scale bar represent percent absolute variability. 
 
In a test-retest reproducibility study of the gold standard TSPO ligand [11C]PK11195 the 
mean absolute variability was calculated (from reported rate constants) to be 15.9 % for VT in 
GM (125), thus similar to the findings  reported on [11C]PBR28 in paper I. However, ICC 
values for GM was considerably lower (0.47) for [11C]PK11195, and in specific brain 
regions, mean difference in binding potential of [11C]PK11195 was much higher than mean 
regional differences of [11C]PBR28 VT, indicating that [11C]PBR28 is more reliable for 
quantification of TSPO levels than [11C]PK11195. 
The findings in paper I of high variability combined with high ICC values for [11C]PBR28 
can mathematically be explained by higher inter-subject variability. Nevertheless, the 
variability discovered in paper I is in line with previous findings of variability in studies of 
[11C]PBR28 (115, 117, 141). Moreover, the lack of reference region for TSPO ligands means 
that analysis of blood data is advisable (142), a procedure that may introduce other sources of 
variation, when several steps of analysis are introduced. In addition, [11C]PBR28 metabolize 
rapidly, thus very small amounts of parent compound remain towards the end of the 
examination. This means that small analytic errors could affect estimation of VT at this stage. 
Thus, alternative methods of quantification without the need for blood data in the analysis, 
such as image-derived input function (143), would be an important goal for future 
methodological research. 
Genotype was not found to affect the absolute variability, thus does not have to be taken into 
account in clinical within-subject studies.   
Since the immune system has been reported to show circadian variation in plasma (144, 145), 
we also investigated whether there were any diurnal changes in TSPO availability. We could 
not detect any significant difference in the main outcome measure between morning and 
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afternoon examinations, although, a trend-level increase in 91 min 2TCM GM VT-values, and 
moreover, significant increases in 63 min 2TCM GM VT and in WAPI-based values were 
demonstrated. In addition, plasma AUC was significantly decreased in the afternoon PET 
examination, as compared to the morning. These findings, although in a limited sample, 
suggest a diurnal component in TSPO availability.  
4.2 PAPER II 
The primary aim of paper II was to investigate the relationship between central and peripheral 
TSPO availability, and a secondary aim to attempt to reduce variability in TSPO binding in 
the brain by accounting for binding in blood cells. Healthy subjects were included (n=32), 
were a subgroup (n=26) had repeat PET measurements. VT in GM was estimated using Logan 
graphical analysis, and TSPO binding in blood cells was calculated from blood and plasma 
radioactivity and hematocrit (HCT) value, according to equation 3, section 3.9.6.  
TSPO in blood cells was lower in MABs than in HABs, at a trend-level significance 
(p=0.066), and both VT brain and VT blood cells of the one LAB individual was <1, 
corroborating lack of specific binding. A strong positive correlation was seen between VT 
brain and VT blood cells among both HABs and MABs together and in both PET 1 and PET 2 
(n=31, r=0.85, p=2.1*10-9). 
 
Figure 8. Scatter-plot of values for VT brain in relation to VT blood cells. Filled dots 
representing HABs, hollow MABs, and x the LAB individual. Dashed line representing the 
regression among HABs, and dotted line among MABs.  
 
Changes in VT brain and VT blood cells were also positively correlated (n=25, r=0.60, 
p=0.002, when LAB individual excluded). The correlation persisted also when dividing 
subjects according to time elapsed between the PET measurements. 
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Figure 9. Scatter plot of % change (∆) in VT brain in relation to change in VT blood cells in 
all individuals with repeat PET measurements. Filled boxes represent PET performed on 
same day, morning and afternoon, blank boxes PET on separate days with short interval, and 
blue boxes on separate days, long interval.  
 
Change in leukocyte numbers and change in VT brain between two successive PET 
examinations was significantly correlated (n=12, r=0.63, p=0.038), whereas change in 
leukocyte numbers correlated on a trend-level significance to change in VT blood cells 
(r=0.60, p=0.052). 
The variability between the two PET measurements for each individual was decreased when 
VT brain was normalized to VT in blood cells (using the ratio of VT brain/VT blood cells), as 
compared to VT brain alone. Thus, coefficient of variance (COV%) was reduced from 40.4 to 
23.4 in HABs and MABs combined, from 34.9 to 22.0 in HABs, and from 37.5 to 22.4 in 
MABs. So, in a comparison with paper I, for the subgroup of subjects investigated with two 
PET measurements, short interval (n=12), the absolute variability was decreased from 20.1 ± 
14.7% (for VT brain) to 12.4 ± 8.4% (for the ratio of VT brain/ VT blood cells). 
The positive correlations between TSPO binding in brain and blood cells, the correlations 
between changes in VT brain and blood cells between repeat measurements, as well as the 
correlations between changes in leukocyte numbers and VT brain indicate an interaction 
between central and peripheral immune cells.  
The brain was long considered an organ immunologically secluded from the rest of the body. 
However, an increasing amount of studies demonstrate an interaction between the immune 
system in the periphery and in the brain (146), In addition, TSPO availability in brain has 
 36 
been shown to increase after peripheral immune activation (147, 148), without disruption of 
the blood brain barrier (BBB). At the same time, interaction between the immune system of 
the periphery and the CNS can also come about via direct entry of immune cells or immune 
markers via the BBB (149), and moreover, a lymphatic system of the brain was recently 
discovered (107). 
Our findings in paper II of interplay between TSPO availability in brain and peripheral blood 
cells in healthy individuals point in the same direction as the current literature, and need to be 
further examined in a clinical setting. 
4.3 PAPER III 
In paper III we aimed to investigate the TSPO availability among a group of neuroleptic-
naïve, first-episode psychotic (FEP) patients, in comparison with healthy control subjects. In 
patients an assessment of psychotic symptoms was performed using PANSS and level of 
functioning using CGI. All subjects underwent assessment of cognitive functioning, with the 
MATRICS battery. Sixteen FEP patients and 16 control subjects were examined with PET 
using [11C]PBR28. The main outcome measure was [11C]PBR28 VT in GM.  
 
Figure 10. Summation PET image in a first-episode psychosis patient using [11C]PBR28. 
We found a significant effect of both TSPO genotype and gender on VT, thus, in the main 
statistical analysis of group difference in VT between patients and controls, used genotype and 
gender as covariates. A significant decrease in VT was found between patients and controls in 
the ANCOVA (F=6.19, df=1.28, p=0.019), more prominent in the subgroup of HAB patients 
(effect size of 0.38 in HABs, as compared to 0.02 in MABs, partial eta squared) (figure 11, 
page 37). The finding remained when excluding the patients that were on medication with 
benzodiazepines at the time of the study (F=6.71, df=1.23, p=0.016). When analyzing 
different brain regions, a significant decrease in patients’ VT was found in hippocampus, 
frontal and temporal cortex, but not in white matter (figure 11). In addition to 2TCM, we also 
performed quantification with 2TCM-1K and DVR. The former rendered a significant 
decrease in patients (F=6.66, df=1.28, p=0.015), but the latter showed no difference between 
the groups, either using 2TCM or 2TCM-1K VT. 
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Figure 11. Jitterplot of regional VT values in FEP patients and controls. Round markers 
representing controls and triangular markers patients, red markers representing HABs and 
blue markers MABs. GM=gray matter, FC=frontal cortex, TC=temporal cortex, 
HIP=hippocampus and WM=white matter. 
 
No correlation was seen between VT and either of the PANSS-scores, CGI or duration of 
illness (DOI). The patients performed worse than the controls in all of the tested domains in 
the MATRICS battery, however, no significant correlation was found between VT and 
cognitive measures after Bonferroni-correction.  
TSPO availability in schizophrenia has been studied only for the last decade. Initial findings 
of elevated TSPO binding (122, 123) has in more recent years been succeeded by 
observations of no difference, or even trend-level decreases in patients (150). Our finding is 
novel in several respects; first, ours is a larger sample than the previous PET studies 
investigating TSPO in schizophrenia, including the ones examining neuroleptic-naïve 
psychotic patients (132, 133) (n=6 and n=14 respectively). Second, the duration of illness 
(DOI) was considerably longer for the neuroleptic-naive patients in both of these studies, 
with DOI of 2 to 6 years (Holmes et al), or a mean of 33.5 months (Hafizi et al) respectively, 
as compared to ours, where it was less than eight months. Third, we used a radioligand with 
improved characteristics, such as increased signal-to-background-noise ratio and higher 
affinity for TSPO, in comparison with the older ligand [11C]PK11195 (151), used by Holmes 
and colleagues.  
We did not find support for the idea that schizophrenia is characterized by activation of 
microglia. Nevertheless, convincing evidence of an alteration of the immune system as part of 
the pathophysiology behind the disease have indeed been demonstrated (75). So how can we 
interpret decreased TSPO availability in FEP?  
VT 
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It may be that the immune system fails to adapt to various pathological processes emerging 
from the psychotic state, and thus may promote the development of the disease. A recent 
finding of a positive association between schizophrenia and the autoimmune disease 
Systemic Lupus Erytematosus (SLE) (152), as well as previous reports of elevated auto-
antibodies in subgroups of patients with psychosis (153), points in this direction. 
Microglia are highly dynamic cells, continuously surveying the surroundings already in their 
non-active state. When triggered by disturbances in the CNS homeostasis, they transform into 
the amoeboid, “active” form, secreting cytokines and chemokines and phagocytosing 
damaged or dying neurons (154). Their activation can be described as a continuum between 
two functional states of polarization; either the classical, pro-inflammatory M1, or the 
alternative, anti-inflammatory M2 (155). The phenotypes of microglia are regulated by pro- 
or anti-inflammatory cytokines, transcription factors, acute phase proteins and differences in 
metabolic states (156), determining whether proliferation, phagocytosis, neuromodulation or 
pruning of superfluous synapses shall be on the agenda (157). Altogether, alterations in 
TSPO may thus reflect differences in microglial activation, and future directions for research 
include characterization of the various microglia phenotypes in relation to TSPO. 
TSPO is not only expressed in microglia, but also in astrocytes and in vascular endothelial 
cells of the brain, as well as in the periphery (158, 159). Thus, lower levels of TSPO binding 
may not reflect a dysfunction of microglia, but of other CNS cells. Moreover, in a recent 
animal study, using an infection-mediated mouse model of neurodevelopmental disruption, 
with disease-relevant behavioral abnormalities, TSPO expression was found to be reduced 
not only in microglia, but also in astrocytes and vascular endothelial cells of the CNS (160). 
Interestingly, according to an ischemic stroke animal model activation of microglia seems to 
be preceding that of astrocytes (161). 
Besides immunological functions, TSPO has been proposed to be involved in the 
steroidogenesis of the cell, in oxidative processes and in the regulation of programmed cell 
deaths (158), and a recent animal study suggests an even more fundamental role for TSPO in 
the energy production of the cell (162). Thus, alterations in TSPO binding in FEP may reflect 
other pathophysiological processes of the disease. 
4.4 PAPER IV 
Our aim with paper IV was to investigate the availability of TSPO in peripheral blood cells of 
FEP and to relate this to TSPO binding in brain. Moreover, we aimed to examine levels of the 
chemokines YKL-40 and MCP-1 in both plasma and CSF in relation to TSPO. 
We estimated TSPO binding in blood in the group of patients and control subjects 
participating in paper III. Of these, 11 patients and 13 control subjects contributed plasma and 
CSF samples for analyses of chemokines. TSPO binding in blood cells was calculated from 
blood and plasma radioactivity and hematocrit (HCT) value, as described previously, and 
chemokines analyzed using electrochemiluminescence assay. 
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No difference was seen in VT blood cells of patients as compared to controls; nevertheless, a 
significant correlation was detected between VT brain and VT blood cells in both patients 
(r=0.63; p=0.017) and controls (r= 0.68; p=0.007) (figure 12). 
 
 
Figure 12. Scatterplots of VT brain in relation to VT blood cells. A) Shows the relationship in 
FEP patients (n=16), where the correlation was significant, controlling for gender and TSPO 
genotype (r=0.63; p=0.017). B) Shows the corresponding relationship among control 
subjects (n=16) (r=0.68; p=0.007). 
A 
B 
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Moreover, the ratio of VT brain/VT blood cells showed significant reduction in patients as 
compared to control subjects (F=16.54, df=1.27, p<0.001) (figure 13). 
 
Figure 13. Showing the ratio between VT brain and VT blood cells in both patients and control 
subjects, with a significant difference between the two groups in an ANCOVA (F=16.54; 
df=1.27; p<0.001), using gender and genotype as covariates. 
In addition, plasma YKL-40 levels were significantly increased in patients, and YKL-40-
levels in CSF and VT brain correlated significantly and positively among patients (r=0.78; 
p=0.021) (figure 14A), whereas in controls these variables were negatively correlated (r=-
0.88; p=0.009) (figure 14B, page 41).  
  
Figure 14 A 
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Figure 14. Scatterplot of the relationship between VT brain and the levels of YKL-40 in CSF, 
with A) (previous page) showing this relationship in patients, with a significant positive 
correlation when controlling for age, gender and genotype (r=0.78; p=0.021), and B) in 
control subjects, where the corresponding correlation was negative (r=0.88; p=0.009). 
 
The observation of a positive correlation between VT in brain and blood cells supports 
maintenance of a peripheral-to-central immune function in FEP patients, even in the absence 
of a significant alteration in TSPO binding in blood cells. Nevertheless, the elevated 
chemokine levels in plasma suggest a pro-inflammatory state in early psychosis.  
Chemokines have been but sparsely investigated in schizophrenia (87), however, an 
increasing amount of studies point to their relevance for the disease (163, 164). YKL-40 is a 
chemokine secreted by both microglia and astrocytes of the CNS, and is thought of as a 
biological marker for non-infectious inflammatory diseases, such as Alzheimers’, Parkinsons’ 
and other neurodegenerative diseases (165). It has also been genetically linked to 
schizophrenia (89–91). Here we present unique data of an association between the chemokine 
YKL-40 in CSF and TSPO binding in brain, in different directions among patients and 
controls respectively, raising further questions about the role of YKL-40 in schizophrenia. 
One explanation to this pattern of disparate correlations is that the relationship between TSPO 
up-regulation in brain and elevations in central YKL-40 expression is put out of action in 
early schizophrenia.  
 
 
Figure 14 B 
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5 SUMMARY OF FINDINGS 
5.1 TEST-RETEST VARIABILITY OF [11C]PBR28 
Mean absolute variability in [11C]PBR28 binding ranged from 13.8 % to 25.9 %, depending 
on the method of quantification used and region examined, and whether or not diurnal 
changes were controlled. Furthermore, ICC values for VT in all GM regions ranged from 
0.90-0.94, indicating a high reliability. A voxel-based quantification approach rendered 
similar reproducibility, and reducing the time to 63 min did not affect variability.  
5.2 RELATIONSHIP BETWEEN TSPO BINDING IN BRAIN AND BLOOD CELLS      
TSPO availability in brain correlated strongly and positively to binding in blood cells, at both 
baseline and when analyzing change between two PET examinations. There was also a 
significant correlation between change in leukocyte numbers and change in TSPO binding in 
brain, and moreover, a trend- level correlation to change in TSPO binding in blood cells. The 
inter-individual variability in brain VT was reduced when controlling for VT in blood cells. 
5.3 ASSESSMENT OF TSPO BINDING IN NEUROLEPTIC-NAÏVE FEP 
PATIENTS 
We demonstrated a significant reduction in [11C]PBR28 binding in patients compared to 
healthy control subjects in GM as well as in secondary regions of interest. There was no 
correlation between GM VT and clinical or cognitive measures, after correction for multiple 
comparisons. 
5.4 COMPARISON OF CENTRAL AND PERIPHERAL IMMUNE CELL ACTIVITY 
IN NEUROLEPTIC-NAÏVE FEP PATIENTS 
There was no difference in TSPO availability in blood cells between patients and controls, 
however, a significant positive correlation was found between TSPO in brain and blood cells, 
of similar magnitude in both groups. The ratio between VT in brain and VT in blood cells was 
significantly lower in patients than in controls. We found no correlation between TSPO 
availability in blood cells and plasma levels of chemokines. Nevertheless, a positive 
correlation between CSF levels of YKL-40 and TSPO in brain was found in patients, while 
this correlation was negative in controls. 
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6 FINAL REMARKS AND FUTURE PERSPECTIVES 
Treating first-episode psychotic patients comprises several obstacles. The suffering individual 
is most often a youth on the threshold of adulthood, surrounded by a family in crisis. The 
available treatment options are insufficient and often leave a lot to be desired. Thus, finding 
paths for novel medical strategies is vital and urgent for treatment development in 
schizophrenia. 
We started this project with the hypothesis that TSPO availability in early schizophrenia 
would be enhanced, due to microglia activation. However, in our clinical study in FEP 
patients we obtained evidence for a decrease in TSPO binding in brain. This finding has an 
essential impact on the field of TSPO PET in schizophrenia, since it rules out the effect of 
neuroleptics on TSPO availability. Furthermore, it raises further questions as to in which cell 
types of the CNS the decreased binding takes place, and if in microglia, which phenotype(s) it 
is that expresses lowered levels of TSPO. Is it mainly the neuroprotective capacity of 
microglia that is affected? One is also tempted to follow up patients included at onset of 
psychosis, to investigate whether TSPO availability differs later on, as the disease progresses. 
A further research direction would be to investigate individuals with respect to TSPO at an 
earlier stage, in order to determine the onset of the disturbance in receptor availability.  
In our final paper we investigated peripheral and central levels of chemokines in the same set 
of patients as in paper III, and found elevations of plasma levels of YKL-40. This chemokine 
has previously been found associated to disease progression in several inflammatory and 
neurodegenerative diseases; however not fully investigated in schizophrenia. Hence, this 
finding is of importance, even though the sample size is small. Moreover, we found 
associations between YKL-40 levels in CSF and TSPO availability in brain, which further 
supports the notion of a disturbance in immune regulation in early psychosis. This 
preliminary study needs to be supplemented with a larger sample of CSF and plasma, in 
relation to TSPO. In addition, to enable differentiation between microglia and astrocytes, 
markers for the latter should be included. 
In the past, attempts at treating schizophrenia with add-on anti-inflammatory medication have 
been made, with some effect on psychotic symptoms. It is not impossible that this may prove 
to be a feasible route in the future. However, before establishing antiphlogistics as clinical 
practice in schizophrenia, a more thorough knowledge is necessary of the role of CNS 
immune cells, within the different phases of the disease. In the quest for a more cohesive 
picture, imaging the TSPO receptor can be helpful in establishing protein expression. 
Furthermore, concomitant evaluation of the different cellular sources of expression is 
necessary, in order to determine the significance of the outcome.  
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